Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near

Exelixis NASDAQ: EXEL remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company's senior vice president of strategy, said during a session hosted by RBC Capital Markets.